The Enterprise Value as of September 2024 (TTM) for Eliem Therapeutics, Inc. (ELYM) is 272.53M

According to Eliem Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 272.53M. This represents a change of -2814.13% compared to the average of -10041333.98 of the last 4 quarters.

Eliem Therapeutics, Inc. (ELYM) Historical Enterprise Value (quarterly & annually)

How has ELYM Enterprise Value performed in the past?

The mean historical Enterprise Value of Eliem Therapeutics, Inc. over the last ten years is 211.25M. The current 272.53M Enterprise Value has changed 12.80% with respect to the historical average. Over the past ten years (40 quarters), ELYM's Enterprise Value was at its highest in in the June 2021 quarter at 273.50M. The Enterprise Value was at its lowest in in the March 2024 quarter at -27418121.60.

Eliem Therapeutics, Inc. (ELYM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Eliem Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Eliem Therapeutics, Inc. (ELYM) Average Enterprise Value

How has ELYM Enterprise Value performed in the past?

The current Enterprise Value of Eliem Therapeutics, Inc. (ELYM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Eliem Therapeutics, Inc. (ELYM) Enterprise Value vs. Peers

How is ELYM’s Enterprise Value compared to its peers?

Eliem Therapeutics, Inc.’s Enterprise Value is greater than PMV Pharmaceuticals, Inc. (40.92M), greater than MediciNova, Inc. (59.15M), less than Pharvaris N.V. (587.59M), greater than PepGen Inc. (241.09M), greater than Anebulo Pharmaceuticals, Inc. (41.53M), greater than Rezolute, Inc. (237.24M), greater than HCW Biologics Inc. (35.48M), greater than Molecular Partners AG (-1929773.37), greater than Aerovate Therapeutics, Inc. (24.46M), greater than Adagene Inc. (40.66M), greater than Acrivon Therapeutics, Inc. Common Stock (208.47M), greater than AN2 Therapeutics, Inc. (3.67M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than Pardes Biosciences, Inc. (34.92M), greater than Shattuck Labs, Inc. (110.17M), greater than Champions Oncology, Inc. (62.59M), greater than Century Therapeutics, Inc. (138.60M),

Build a custom stock screener for Eliem Therapeutics, Inc. (ELYM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eliem Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Eliem Therapeutics, Inc. (ELYM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Eliem Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.